Get Consultation

Clinical Evidence & Lifecycle Strategy

Clinical evidence is a capital allocation decision. It shapes approval durability, post-market burden, lifecycle cost, and valuation trajectory.

SHOTUNE provides founder-led clinical strategy for Class I–III medical devices where evidence must withstand FDA, EU MDR, audit, and diligence scrutiny.

Request a Confidential Clinical Strategy Discussion
A focused discussion to assess evidence risk, clinical options, and the decisions that matter next.

What This Protects

Regulatory claims and benefit-risk defensibility

Approval durability across the device lifecycle

PMCF, PMS, and post-market evidence readiness

Capital discipline in study design and evidence planning

Over-studying destroys capital. Under-studying destroys approvals. Governance prevents both.

Escalate Clinical Strategy When

  • Clinical evidence does not adequately support regulatory claims
  • CER, CEP, PMCF, PMS, and risk logic are not aligned
  • Studies are underway but no longer clearly support the approval strategy
  • Leadership needs to avoid unnecessary additional studies or delayed approval
  • Evidence decisions are beginning to affect commercial timing or valuation

Why Teams Escalate Clinical Strategy to SHOTUNE

  • CROs execute studies, but do not own enterprise evidence strategy
  • Academic advisors may strengthen scientific rigor, but not always regulator alignment or commercial realism
  • Internal teams often understand the problem, but lack the bandwidth or senior judgment to re-architect evidence under pressure

SHOTUNE is engaged when clinical strategy must support approvals, claims, PMCF, and commercial timing—not just study execution.

Strategic Scope

CER, CEP, PMCF, and PMS strategy

Evidence-gap assessment and remediation planning

Clinical proportionality and study architecture decisions

Claims support and benefit-risk alignment

Lifecycle evidence strategy tied to post-market obligations

How We Work

SHOTUNE evaluates whether your current evidence strategy is strong enough to support approval, defend claims, and withstand post-market scrutiny.

Where gaps exist, we help leadership realign the evidence plan, reduce unnecessary study burden, and create a clinical strategy that is regulator-aligned, proportionate, and commercially relevant.

Execution follows strategy—not the reverse.

What an Initial Clinical Engagement May Include

  • Evidence-gap assessment across CER, CEP, PMCF, PMS, and claims
  • Clinical proportionality decisions grounded in regulatory and commercial risk
  • Remediation options for legacy or misaligned clinical programs
  • A prioritized path forward for leadership, regulatory, and clinical teams

Founder Accountability

  • Every clinical engagement is personally led by Shola Sulaimon. Clients receive direct senior judgment across evidence strategy, regulator expectations, and lifecycle risk—not disconnected study advice.

FAQs

1. How does SHOTUNE design clinical strategy to meet FDA and EU MDR expectations?

SHOTUNE designs clinical strategy around regulator decisions, not data accumulation. For startups, that helps prevent overbuilding or underbuilding the evidence plan. For more mature organizations, it helps ensure evidence remains aligned to claims, benefit-risk, and lifecycle obligations as the product and markets evolve.

Yes. For smaller companies, that may mean identifying the minimum defensible path forward before capital is consumed on the wrong work. For larger organizations, it often means determining whether the issue is a true evidence gap, a claims problem, or a broader strategy misalignment.
Yes. SHOTUNE is often brought in when an active or legacy program no longer supports current regulatory expectations or commercialization goals. We reassess what the data can credibly support, what needs to change, and how to move forward without unnecessary additional burden.
Notified Body pushback usually reflects concern with the underlying evidence logic, not just the wording. SHOTUNE helps realign CER, PMCF, claims, and benefit-risk rationale so the full story is more coherent, defensible, and commercially realistic.
Yes. For growth-stage and larger manufacturers especially, PMS and PMCF should not be treated as disconnected compliance activity. SHOTUNE helps design proportionate post-market strategies that meet expectations, preserve resources, and support lifecycle decision-making across markets.
Clinical evidence is not credible in isolation. SHOTUNE aligns evidence, claims, risk management, and post-market processes so your organization can defend one integrated position across regulatory, clinical, and quality functions.

Need Greater Confidence in the Evidence Strategy Behind Approval?

A focused discussion to assess evidence risk, clinical options, and the decisions that matter next.
Request a Confidential Clinical Strategy Discussion
Scroll to Top